Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Microbicide Trial “Condom Only”-Arm Designs To Be Reviewed By FDA Cmte.

This article was originally published in The Tan Sheet

Executive Summary

FDA is seeking guidance from the Antiviral Drugs Advisory Committee as to whether clinical trials on topical microbicides should include a "no treatment" (condom only) arm
Advertisement

Related Content

Microbicide Trial Three-Arm Design May Be Optimal Initially – Panelists
Microbicide Trial Design Flexibility Supported At FDA Advisory Panel Meeting
Microbicide Trial Three-Arm Design May Be Optimal Initially – Panelists
Microbicide Trial Design Flexibility Supported At FDA Advisory Panel Meeting
Microbicide Trial Three-Arm Design May Be Optimal Initially – Panelists
Vaginal Contraceptive N-9 Label Warnings Urged “As Soon As Possible” – FDA
N-9 Data Warrants Spermicide Safety Study, WHO Report Recommends
N-9 Lubricated Condom Buys, Spermicide Use Discouraged In CDC Guidelines
Columbia Labs Advantage-S Additional HIV Prevention Trials Unlikely
Columbia Labs Advantage-S Additional HIV Prevention Trials Unlikely

Topics

Advertisement
UsernamePublicRestriction

Register

PS095820

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel